Benchling has launched its inaugural 2023 State of Tech in Biopharma report, which has make clear the obstacles that biopharma encounter when striving to totally implement and embrace these applied sciences.
The report surveyed 300 R&D and IT specialists from biopharma firms giant and small to do a first-ever investigation into biopharma’s use of an enabling tech stack — consisting of robotics and automation, related devices, R&D information platforms, cloud-based scientific purposes, and AI and ML.
The report finds that the biopharma business is extensively adopting enabling tech, with R&D information platforms essentially the most extensively adopted (at 70%), adopted by robotics and automation platforms (63%), AI and ML (59%). However, the adoption of SaaS software program is lagging, with solely 18% of respondents utilizing it for almost all of their R&D and IT work.
This excessive tech adoption has additionally corresponded with a fancy tech surroundings in labs — with 53% of scientists utilizing 5+ distinctive scientific software program purposes every day, and 40% of IT at giant firms supporting greater than 20 purposes. 84% are utilizing some custom-built software program, indicating a holdover of legacy techniques. In addition, 41% of scientists discover collaborating with and throughout groups a problem, and 38% are needing to collaborate with 20 or extra folks of their day-to-day work.
With such complexity, FAIR information rules are nonetheless out of attain – with restricted progress in reaching organisation-wide information interoperability (I) at 28%, and information reusability (R) at 30%.
The report additionally reveals that the 2 largest obstacles to adopting enabling tech and having the ability to work with it successfully is a scarcity of expert expertise, and science-specific options. This exhibits a transparent name to motion for the business to spend money on attracting the appropriate expertise to work with rising applied sciences, and people who have a powerful want to construct new, fit-for-purpose scientific software program that may delight scientists and unlock IT groups.
Benchling’s analysis reveals firms additionally have to take a logical step of fostering stronger alignment between their R&D and IT organisations — together with rationalising divergent tech priorities and having an sincere dialogue on the actual obstacles to adoption, similar to organisational tradition and alter administration. In the approaching years, the significance of scientific information and AI will solely develop, placing further stress on biopharma to desert legacy tech and construct a stronger digital basis.
Bob Burke, EMEA GM at Benchling, stated: “We’re witnessing a remarkable era in biopharma, where groundbreaking therapies and technological innovations are reshaping disease prevention and treatment. Enabling tech is helping companies bring the power of automation, cloud, and AI to bear on problems of speed, quality, success, and scalability in biopharma.
“Our report highlights the hurdles that must be surmounted to accelerate scientific progress. In the years ahead, scientific data and AI will gain even greater significance, intensifying the need for biopharma to shed legacy tech and fortify its digital foundation. Companies capable of attracting top talent, fostering alignment between R&D and IT, and swiftly adopting new technologies, the right technologies which are built for this new era of biology, are poised to become the most influential players in biopharma, driving success for generations to come”.
“To propel the UK toward its science superpower vision, it is imperative that we attract more technical talent to the life sciences industry, upskill and train existing employees, and prioritise user-friendly and built-for-biology SaaS and tech tools. Talent is here and the roots are here but we need to do a better job of connecting the dots between tech innovation and the opportunity in life sciences.”
About Benchling
Benchling is the pioneer of the R&D Cloud, software program that unlocks the ability of biotechnology. More than 200,000 scientists at over 1,200 firms and seven,500 tutorial and analysis establishments globally have adopted the Benchling R&D Cloud to make breakthrough discoveries and convey the subsequent era of medicines, meals, and supplies to market quicker. The Benchling R&D Cloud helps these organisations modernise their scientific processes and speed up collaboration to allow them to convert the complexity of biology into world-changing outcomes. For extra, please go to Benchling.com.
Methodology The report relies on a web based survey performed from July thirteenth to August 1st, with 300 respondents from the prescription drugs and biotechnology business. Respondents included 59% from R&D and 41% from IT, with 55% from giant firms and 45% from small firms.
Want to study extra about cybersecurity and the cloud from business leaders? Check out Cyber Security & Cloud Expo going down in Amsterdam, California, and London. Explore different upcoming enterprise expertise occasions and webinars powered by TechForge right here.